Isolation of Trypanosoma brucei gambiense from cured and relapsed sleeping sickness patients and adaptation to laboratory mice

PLoS Neglected Tropical Diseases

Volumn 5, Issue 4, 2011, Pages

  Pyana, Patient Pati ^a,b   Lukusa, Ipos Ngay ^a   Ngoyi, Dieudonné Mumba ^a,b   van Reet, Nick ^b   Kaiser, Marcel ^c,d   Shamamba, Stomy Karhemere Bin ^a   Büscher, Philippe ^b  

^a Institut National de Recherche Biomedicale   (Congo)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; GLUCOSE; LIQUID NITROGEN; MELARSOPROL; NIFURTIMOX; PENTAMIDINE; ANTIPROTOZOAL AGENT;

AFRICAN TRYPANOSOMIASIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; CONGO; CONTROLLED STUDY; CRYOPRESERVATION; DRUG TREATMENT FAILURE; FEMALE; FROZEN SECTION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INOCULATION; MALE; MASTOMYS; MOUSE; NONHUMAN; PARASITE ISOLATION; RELAPSE; SCID MOUSE; STRAIN DIFFERENCE; TRYPANOSOMA GAMBIENSE; ADAPTATION; ANIMAL; BLOOD; CEREBROSPINAL FLUID; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; PARASITOLOGY; RECURRENT DISEASE; TRYPANOSOMA;

ADAPTATION, BIOLOGICAL; ANIMALS; ANTIPROTOZOAL AGENTS; BLOOD; CEREBROSPINAL FLUID; FEMALE; HUMANS; MALE; MELARSOPROL; MICE; RECURRENCE; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMIASIS, AFRICAN;

EID: 79955847165     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001025     Document Type: Article

References (30)

1. Simarro PP, Jannin J, Cattand P, (2008) Eliminating human African trypanosomiasis: Where do we stand and what comes next? PLoS Medicine 5: 174-180.
2. Brun R, Blum J, Chappuis F, Burri C, (2010) Human African trypanosomiasis. Lancet 375: 148-159.
3. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, et al. (2009) Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374: 56-64.
4. Pépin J, Milord F, Khonde A, Niyonsenga T, Loko L, et al. (1994) Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy. Trans R Soc Trop Med Hyg 88: 447-452.
5. Robays J, Nyamowala G, Sese C, Kande Betu-Ku-Mesu V, Lutumba P, et al. (2008) High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo. Em Inf Dis 14: 966-967.
6. Mumba Ngoyi D, Lejon V, Pyana P, Boelaert M, Ilunga M, et al. (2010) How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness? J Infect Dis 201: 453-463.
7. Legros D, Ollivier G, Gastellu-Etchegorry M, Paquet C, Burri C, et al. (2002) Treatment of human African trypanosomiasis- present situation and needs for research and development. Lancet Infect Dis 2: 437-440.
8. Stanghellini A, Josenando T, (2001) The situation of sleeping sickness in Angola: a calamity. Trop Med Int Health 6: 330-334.
9. Brun R, Schumacher R, Schmid C, Kunz C, Burri C, (2001) The phenomenon of treatment failures in human African trypanosomiasis. Trop Med Int Health 6: 906-914.
10. Moore A, Richer M, (2001) Re-emergence of epidemic sleeping sickness in southern Sudan. Trop Med Int Health 6: 342-347.
11. Carter NS, Fairlamb AH, (1993) Arsenical resistant trypanosome lack the unusual adenosine transporter. Nature 361: 173-175.
12. Mäser P, Sütterlin C, Kralli A, Kaminsky R, (1999) A nucleoside transporter from Trypanosoma brucei involved in drug resistance. Science 285: 242-244.
13. de Koning HP, (2008) Ever-increasing complexities of diamidine and arsenical crossresistance in African trypanosomes. Trends Parasitology 24: 345-349.
14. Maina N, Maina KJ, Mäser P, Brun R, (2007) Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure. Acta Trop 104: 84-90.
15. Matovu E, Enyaru JCK, Legros D, Schmid C, Seebeck T, et al. (2001) Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda. Trop Med Int Health 6: 407-411.
16. Matovu E, Geiser F, Schneider V, Mäser P, Enyaru JCK, et al. (2001) Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy. Mol Biochem Parasitol 117: 73-81.
17. Lékané Likeufack AC, Brun R, Fomena A, Truc P, (2006) Comparison of the in vitro drug sensitivity of Trypanosoma brucei gambiense strains from West and Central Africa isolated in the periods 1960-1995 and 1999-2004. Acta Trop 100: 11-16.
18. Büscher P, Kahremere Bin Shamamba S, Mumba D, Pyana P, Baelmans R, et al. (2005) Susceptibility of Grammomys surdaster thicket rats for Trypanosoma brucei gambiense infection. Trop Med Int Health 10: 850-855.
19. Maina NW, Kunz C, Brun R, (2006) Cryopreservation of Trypanosoma brucei gambiense in a commercial cryomedium developed for bull semen. Acta Trop 98: 207-211.
20. Maina NW, Oberle M, Otieno C, Kunz C, Maeser P, et al. (2007) Isolation and propagation of Trypanosoma brucei gambiense from sleeping sickness patients in south Sudan. Trans R Soc Trop Med Hyg 101: 540-546.
21. Herbert WJ, Lumsden WHR, (1976) Trypanosoma brucei: A rapid "matching" method for estimating the host's parasitemia. Exp Parasitol 40: 427-431.
22. Radwanska M, Chamekh M, Vanhamme L, Claes F, Magez S, et al. (2002) The serum resistance-associated gene as a diagnostic tool for the detection of Trypanosoma brucei rhodesiense. Am J Trop Med Hyg 67: 684-690.
23. Welburn SC, Picozzi K, Fèvre EM, Coleman PG, Odiit M, et al. (2001) Identification of human-infective trypanosomes in animal reservoir of sleeping sickness in Uganda by means of serum-resistance-associated (SRA) gene. Lancet 358: 2017-2019.
24. Aerts D, Truc P, Penchenier L, Claes Y, Le Ray D, (1992) A kit for in vitro isolation of trypanosomes in the field: first trial with sleeping sickness patients in the Congo Republic. Trans R Soc Trop Med Hyg 86: 394-395.
25. Dukes P, Kaukas A, Hudson KM, Asonganyi T, Gashumba JK, (1989) A new method for isolating Trypanosoma brucei gambiense from sleeping sickness patients. Trans R Soc Trop Med Hyg 83: 636-639.
26. Giroud C, Ottones F, Coustou V, Dacheux D, Biteau N, et al. (2009) Murine models for Trypanosoma brucei gambiense disease progression-from silent to chronic infections and early brain tropism. PLoS Negl Trop Dis 3: e509.
27. Schmid C, Richer M, Bilengue MMC, Josenando T, Chappuis F, et al. (2005) Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). J Infect Dis 191: 1922-1931.
28. Koffi M, Solano P, Barnabe C, De MT, Bucheton B, et al. (2007) Genetic characterisation of Trypanosoma brucei s.l. using microsatellite typing: new perspectives for the molecular epidemiology of human African trypanosomiasis. Infect Genet Evol 7: 675-684.
29. Morrison LJ, Tait A, McCormack G, Sweeney L, Black A, et al. (2008) Trypanosoma brucei gambiense Type 1 populations from human patients are clonal and display geographical genetic differentiation. Infect Genet Evol 8: 847-854.
30. Jamonneau V, Garcia A, Ravel S, Cuny G, Oury B, et al. (2002) Genetic characterization of Trypanosoma brucei gambiense and clinical evolution of human African trypanosomiasis in Côte d'Ivoire. Trop Med Int Health 7: 610-621.